

1647
HY
AP



Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (6-98)
Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/929,986	
	Filing Date	August 14, 2001	
	First Named Inventor	Olivier Civelli et al.	
	Group Art Unit	1647	
	Examiner Name		
Total Number of Pages in This Submission	5	Confirmation Number	9873

RECEIVED

FEB 04 2002

TECH CENTER 1600/2900

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Additional Enclosure(s) (please identify below):
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	F. Aaron Dubberley
Signature	<i>F. Aaron Dubberley</i>
Date	November 13, 2001

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail on the date shown below in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231:		
Typed or printed name	F. Aaron Dubberley	
Signature	<i>F. Aaron Dubberley</i>	Date
		November 13, 2001

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

FEB 04 2002

TECH CENTER 1600/2900

In re Patent Application

Civelli et al.

Group: 1647

Serial No.09/929,986, filed August 14, 2001

Examiner:

For: **METHOD OF IDENTIFYING COMPOUNDS HAVING ANTIEPILEPTIC,
ANTICONVULSANT OR ANXIOLYTIC ACTIVITIES**

INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110
November 13, 2001

Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.


None of the documents listed on Form PTO 1449 are being submitted because each document has been made of record in the parent application, Serial No. 09/868,355, filed June 3, 1997.

Consideration of all the documents cited on Form PTO-1449 is requested.

Serial No. 09/929,986
Filed August 14, 2001

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application, no fee is due.

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "F. Aaron Dubberley", is written over a horizontal line.

Agent for Applicant(s)

F. Aaron Dubberley

(Reg. No. 41001)

340 Kingsland Street

Nutley, New Jersey 07110

Telephone: (973) 235-4387

Telefax: (973) 235-2363


115521

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Application Number	09/929,986
		Filing Date	August 14, 2001
		First Name Inventor	Civelli et al.
		Group Art Unit	1647
		Examiner Name	
		Attorney Docket Number	9516
Sheet	2	Of	2

RECEIVED

FEB 04 2002

TECH CENTER 1600/2900



Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ¹
SC	C1	Bunzow et al., FEBS Letters, Vol. 347, pages 284-288 (1994)	
u	C2	Chen et al., FEBS Letters, Vol. 347, pages 279-283 (1994)	
u	C3	Fukuda et al., FEBS Letters, Vol. 343, pages 42-46 (1994)	
u	C4	Mollereau et al., FEBS Letters, Vol. 341, pages 33-38 (1994)	
u	C5	Wang et al., FEBS Letters, Vol. 348, pages 75-79 (1994)	
u	C6	Lachowicz et al., Journal of Neurochemistry, Vol. 64, No. 1 pages 34-40 (1995)	
u	C7	Nishi et al., Biochemical and Biophysical Research Communications, Vol. 205, No. 2, pages 1353-1357 (1994)	
u	C8	Wick et al., Molecular Brain Research, Vol. 27 pages 37-44 (1994)	
u	C9	Meunier et al., Nature, Vol. 377, pages 532-535 (1995)	
u	C10	Reinscheid et al., Science, Vol. 270, pages 792-794 (1995)	
u	C11	Vaughan et al., British Journal of Pharmacology Vol. 117, pages 1609-1611 (1996)	
u	C12	David Julius, Nature, Vol. 377, page 476 (1995)	
u	C13	Zhang et al., The Journal of Biological Chemistry, Vol. 270, No. 39, pages 22772-22776 (1995)	
u	C14	Jenck, et al., Proc. Natl. Acad. Sci., Vol 94, pages 14854-14858 (1997)	
u	C15	Reinscheid et al., J. Biol. Chem., Vol. 271, No. 24, pages 14163-14168 (1996)	
u	C16	Zezula et al., Neurosci., Vol. 25, pages 771-795, 1988 (Abstract only)	
u	C17	Ono et al., Arzneimittel Forschung, Vol. 37, pages 384-388 (Abstract only) NEED DATE	
	C18	Rocha et al., Brain Res., Vol. 612, pages 247-252, 1993	
Examiner Signature	Stephen Jucke		DATE CONSIDERED 10/1/03

*EXAMINER: Initial, if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation or abstract is attached.

114552